{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:52:48Z","timestamp":1791899568967,"version":"4.3.4"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1001\/jamapediatrics.2018.2143","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T15:50:10Z","timestamp":1536767410000},"page":"1029","source":"Crossref","is-referenced-by-count":205,"title":["Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder"],"prefix":"10.1001","volume":"172","author":[{"given":"Scott E.","family":"Hadland","sequence":"first","affiliation":[{"name":"Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts"},{"name":"Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts"},{"name":"Department of Pediatrics, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Bagley","sequence":"additional","affiliation":[{"name":"Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts"},{"name":"Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts"},{"name":"Department of Pediatrics, Boston Medical Center, Boston, Massachusetts"},{"name":"Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rodean","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Association, Lenexa, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Silverstein","sequence":"additional","affiliation":[{"name":"Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Levy","sequence":"additional","affiliation":[{"name":"Adolescent Substance Use and Addictions Program, Division of Developmental Medicine, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Larochelle","sequence":"additional","affiliation":[{"name":"Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts"},{"name":"Department of Pediatrics, Boston Medical Center, Boston, Massachusetts"},{"name":"Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[{"name":"Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts"},{"name":"Department of Pediatrics, Boston Medical Center, Boston, Massachusetts"},{"name":"Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie T.","family":"Zima","sequence":"additional","affiliation":[{"name":"Semel Institute for Neuroscience and Human Behavior, UCLA (University of California, Los Angeles), Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"poi180052r1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014.","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"12","key":"poi180052r2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamapediatrics.2016.2154","article-title":"National trends in hospitalizations for opioid poisonings among children and adolescents, 1997 to 2012.","volume":"170","author":"Gaither","year":"2016","journal-title":"JAMA Pediatr"},{"issue":"17","key":"poi180052r4","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged =30 years\u2014Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012.","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"poi180052r5","doi-asserted-by":"publisher","first-page":"e20161893","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders.","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"issue":"5","key":"poi180052r8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use.","volume":"9","author":"Kampman","year":"2015","journal-title":"J Addict Med"},{"issue":"6","key":"poi180052r9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","article-title":"Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder.","volume":"60","author":"Feder","year":"2017","journal-title":"J Adolesc Health"},{"issue":"1","key":"poi180052r10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder.","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Ann Fam Med"},{"issue":"6","key":"poi180052r11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/ADM.0000000000000348","article-title":"Addressing stigma in medication treatment of adolescents with opioid use disorder.","volume":"11","author":"Bagley","year":"2017","journal-title":"J Addict Med"},{"issue":"2","key":"poi180052r12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: assessing the evidence.","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"9776","key":"poi180052r13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"poi180052r14","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/add.2009.104.issue-7","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"key":"poi180052r15","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"poi180052r16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1370\/afm.2098","article-title":"Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study.","volume":"15","author":"Dupouy","year":"2017","journal-title":"Ann Fam Med"},{"issue":"3","key":"poi180052r17","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jsat.2014.04.006","article-title":"Emerging adult age status predicts poor buprenorphine treatment retention.","volume":"47","author":"Schuman-Olivier","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"poi180052r18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","article-title":"Long-term retention in office based opioid treatment with buprenorphine.","volume":"74","author":"Weinstein","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"1-2","key":"poi180052r19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: results from a multisite study.","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"poi180052r20","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.","volume":"111","author":"Marsch","year":"2016","journal-title":"Addiction"},{"issue":"17","key":"poi180052r21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA"},{"issue":"10","key":"poi180052r22","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.","volume":"62","author":"Marsch","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"1-3","key":"poi180052r23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.drugalcdep.2011.10.016","article-title":"The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.","volume":"123","author":"Stein","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"poi180052r24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.drugalcdep.2012.01.011","article-title":"The Washington circle engagement performance measures\u2019 association with adolescent treatment outcomes.","volume":"124","author":"Garnick","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"poi180052r26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jsat.2015.01.002","article-title":"Examining the specification validity of the HEDIS quality measures for substance use disorders.","volume":"53","author":"Harris","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"poi180052r27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2016.05.002","article-title":"Impact of medication-assisted treatment for opioid addiction on Medicaid expenditures and health services utilization rates in Vermont.","volume":"67","author":"Mohlman","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"poi180052r28","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/jama.2017.7818","article-title":"Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid.","volume":"318","author":"Frazier","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"poi180052r30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1542\/peds.2013-3165","article-title":"Common and costly hospitalizations for pediatric mental health disorders.","volume":"133","author":"Bardach","year":"2014","journal-title":"Pediatrics"},{"issue":"1","key":"poi180052r32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2007.64","article-title":"Trends in opioid prescribing by race\/ethnicity for patients seeking care in US emergency departments.","volume":"299","author":"Pletcher","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"poi180052r33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamapsychiatry.2015.2132","article-title":"Epidemiology of DSM-5 drug use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions\u2013III.","volume":"73","author":"Grant","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"poi180052r35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11414-008-9142-2","article-title":"Does meeting the HEDIS substance abuse treatment engagement criterion predict patient outcomes?","volume":"37","author":"Harris","year":"2010","journal-title":"J Behav Health Serv Res"},{"issue":"10","key":"poi180052r36","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jamainternmed.2017.3947","article-title":"Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial.","volume":"177","author":"Watkins","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"8","key":"poi180052r38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The role of behavioral interventions in buprenorphine maintenance treatment: a review.","volume":"174","author":"Carroll","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"3","key":"poi180052r41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/add.12821","article-title":"Commentary on Metrebian et al (2015): what is addiction treatment research about? some comments on the secondary outcomes of the Randomized Injectable Opioid Treatment Trial.","volume":"110","author":"Uchtenhagen","year":"2015","journal-title":"Addiction"},{"issue":"5","key":"poi180052r42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.","volume":"171","author":"Alford","year":"2011","journal-title":"Arch Intern Med"},{"key":"poi180052r43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers.","volume":"60","author":"LaBelle","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"11","key":"poi180052r44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMp1613651","article-title":"Another senseless death\u2014the case for supervised injection facilities.","volume":"376","author":"Wakeman","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"poi180052r45","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/jamapediatrics.2017.1269","article-title":"Closing the medication-assisted treatment gap for youth with opioid use disorder.","volume":"171","author":"Saloner","year":"2017","journal-title":"JAMA Pediatr"},{"key":"poi180052r3","author":"Curtin","year":"2017"},{"key":"poi180052r6","volume-title":"Facing Addiction in America: The Surgeon General\u2019s Report on Alcohol, Drugs, and Health","author":"US Dept of Health and Human Services (HHS) Office of the Surgeon General","year":"2016"},{"key":"poi180052r7","volume-title":"Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series, No. 40","author":"Center for Substance Abuse Treatment","year":"2004"},{"key":"poi180052r25","volume-title":"The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions","author":"American Society of Addiction Medicine","year":"2013","edition":"3rd ed"},{"key":"poi180052r34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-4419-6646-9_4","volume-title":"Survival Analysis","author":"Kleinbaum","year":"2012"},{"key":"poi180052r37","author":"Chou","year":"2016"},{"key":"poi180052r39","volume-title":"The ASAM Performance Measures For the Addiction Specialist Physician","author":"American Society for Addiction Medicine","year":"2014"},{"key":"poi180052r29","unstructured":"Agency for Healthcare Research and Quality. Clinical Classifications Software (CCS) for ICD-9-CM. https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs\/ccs.jsp#overview. Published March 2017. Accessed August 17, 2017."},{"key":"poi180052r31","unstructured":"Centers for Disease Control and Prevention. Prescription drug overdose data & statistics: guide to ICD-9-CM and ICD-10 codes related to poisoning and pain. https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pdo_guide_to_icd-9-cm_and_icd-10_codes-a.pdf. Revised August 12, 2013. Accessed August 17, 2017."},{"key":"poi180052r40","unstructured":"New York State Department of Health. Medicaid redesign team (MRT) behavioral health reform work group final recommendations. https:\/\/www.health.ny.gov\/health_care\/medicaid\/redesign\/docs\/mrt_behavioral_health_reform_recommend.pdf. Published October 15, 2011. Accessed December 27, 2017."},{"key":"poi180052r46","unstructured":"Substance Abuse and Mental Health Services Administration. Map\u2014SAMHSA behavioral health treatment services locator. https:\/\/findtreatment.samhsa.gov\/locator. Accessed February 26, 2018."},{"key":"poi180052r47","unstructured":"Substance Abuse and Mental Health Services Administration. WachinoV, HydePS. Coverage of behavioral health services for youth with substance use disorders. https:\/\/www.medicaid.gov\/federal-policy-guidance\/downloads\/cib-01-26-2015.pdf. Published January 26, 2015. Accessed December 1, 2017."}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2698965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T11:02:30Z","timestamp":1541415750000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpedi.jamanetwork.com\/article.aspx?doi=10.1001\/jamapediatrics.2018.2143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2018.2143","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}